RESAPP HEALTH LIMITED (ASX:RAP) - RAP - The Next Phase, page-8 - HotCopper | ASX Share Prices, Stock Market & Share Trading Forum

Originally posted by Wise_One ↑

Hi All, as a RAPper from the beginning, I thought it would be nice to provide a summary of where we are and what we have to expect over the remainder of Q2 for which we now officially enter the 2nd half of the quarter!

From a news-flow perspective, the next 6 weeks could see the following Anns:
- Partner for US trial (imminent)
- Interim Adult trial results
- Update on WHO partnership (possible)
- MOU with telehealth provider (possible)
- Global Expansion Update (possible - see below for more detail)
- FDA Submission (end of Q2)

I would also like to reinforce some excellent points from the latest investor presentation (3 May - note the relevant page numbers of the slides below) which include:
- Targeting parallel approval in Europe (CE MARK) - page 11
- "Active Partnership Discussions in ALL regions" - page 11
- "Clinical collaborations to be announced shortly" - page 13
- "Potential European, Australian and Asian market entry in parallel to US" - page 16

With all of this taken in to consideration, coupled with the passing of 4-weeks since the CR to allow for staggers to exit, it is no coincidence that we saw a rush of volume / price late last week which IMO will continue and be consistently strong until the end of Q2.

Also note that we are presenting in the "ASX Spotlight Series - Asia" in Singapore (24-May) and Hong Kong (26-May). It has been a nice pattern of late that huge milestones are ticked off prior to a fresh round of investor briefings and again, the timing of these presentations to international investors is no coincidence IMO.

I am expecting one of the above milestones to be announced this week which should see RAP hit all time highs (>32c) and then there will be no stopping the train as the remainder of the Q2 milestones are ticked off.

Longer term, $1-$2 by FDA approval is well & truly in sight which will see RAP become a >$1B Mkt Cap company before the end of the year!

A final little note is that we have been consistently trading above 150m Mkt Cap for a while now which will put us in line for ASX300 admission upon the next index rebalance. This will see mandatory buying from index related funds... adding to the RAP demand!!

Expand

Wrote an email to the company, got an immediate response.
Asked for the accuracy of the adult results and status of the FDA approval.

Of course, Mr. Leeman did not know about adult results yet
but mentioned "as for FDA approval, that will follow the commencement of the new pivotal study due to start shortly in the US."

Which teels me a partner has already been found and we can expect an announcement soon.

The clock is ticking...